Valion Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.1M
- Price
- $2.38
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.03%
- Volume
- 126.6K
About
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Quick stats
Shares outstanding1.3M
Computed float1.2M
Float / shares92.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001787740
Websitehttps://valionbio.com
AI Summary
AI-generated1/22
minorneutralboard change
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
Valion Bio highlighted the perspectives of new Board Chair Thomas H. Jensen on advancing Entolimod, a TLR5 agonist in development as a medical countermeasure for acute radiation syndrome.
The release notes roughly $35.6 million in non-dilutive U.S. government funding, FDA Fast Track and Orphan Drug designations, and supply-chain control via its wholly owned CDMO Velocity Bioworks.
Jensen, CEO of Allarity Therapeutics, is working with Interim CEO Dean Zikria and President/COO/CFO Lisa Wolf on milestone sequencing; no new clinical data or specific guidance was announced.
Red flags
- Interim CEO still in place — leadership instability
- Forward-looking statements cite risk to continued Nasdaq listing compliance